Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

Building on the Merck Foundation's longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country

The Merck Foundation announced today the launch of the Collaborative for Equity in Cardiac Care, a $22 million, five-year initiative aimed at enhancing access to high-quality, person-centered health care for people living with heart conditions in the U.S. Eleven organizations are receiving grants to support the development and implementation of evidence-informed, comprehensive programs to improve health outcomes in communities where access to timely care for cardiovascular disease is a challenge.

"Cardiovascular disease continues to be the number one cause of death for men and women living in the U.S., and its burden hits under-resourced communities the hardest. By addressing the medical and social needs of people living with heart conditions, the Collaborative for Equity in Cardiac Care will have a significant, lasting impact on the health and wellbeing of individuals and communities across the country," said Kalahn Taylor-Clark, vice president and head, Social Impact & Sustainability, Merck.

The Foundation is providing grants to select non-profit health care and public health organizations working with local community-based groups. As a Collaborative, they will help bridge gaps in the delivery of care for a range of heart conditions and advance sustainable, and potentially scalable, approaches to improve the lives of people with heart disease.

Collaborative program grantees include:

The Foundation is also supporting the Johns Hopkins Center for Health Equity as the Collaborative's National Program Office (NPO), which will provide technical assistance to grantees as they build local partnerships and implement their programs. The NPO will also foster peer-to-peer learning among grantees, conduct a cross-site evaluation and disseminate the Collaborative's results and lessons learned.

"Collaborative grantees serve a range of populations, and each one has firsthand experience in addressing the specific gaps in access to high-quality cardiac care in their communities," says Lisa A. Cooper, MD, MPH, MACP, director at Johns Hopkins Center for Health Equity and director of the Collaborative NPO. "Bringing together these outstanding organizations to strengthen local partnerships and address the social and environmental factors that influence health will not only meet immediate patient need but also pave the way for sustained improvements in the delivery of cardiac care across the U.S."

The Collaborative for Equity in Cardiac Care builds on the Foundation's legacy of investing in community-focused programs that improve access to high-quality health care in underserved communities, including the Alliance for Equity in Cancer Care , which is currently operating in seven states.

About the Merck Foundation
The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a leading global biopharmaceutical company, the Foundation is funded entirely by the company and is Merck's chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Foundation has contributed more than $1 billion to support important initiatives that address critical global health and societal needs that are consistent with Merck's purpose: to save and improve lives around the world. For more information, visit https://www.merck.com/company-overview/sustainability/philanthropy/

Media Contacts:
John Cummins
john.cummins2@merck.com

Ned Ehrbar
ned.ehrbar@merck.com

News Provided by Business Wire via QuoteMedia

MRK
The Conversation (0)
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...
OTC:BCTXF

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
OTC:BCTXF

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); Bria-IMT™ in combination with INCMGA00012 (by Incyte... Keep Reading...

Latest Press Releases

Related News